Kalypsys Inc., of San Diego, added Stewart Noble as director of chemistry and Tadimeti Rao as director of pharmacology and preclinical development.
Massachusetts Biotechnology Council in Cambridge added Vicki Greene as director of communications.
Maxygen Inc., of Redwood City, Calif., appointed James Sulat to its board.
NeurogesX Inc., of San Carlos, Calif., appointed Stephen Ghiglieri chief financial officer.
Novavax Inc., of Columbia, Md., added Ford Lynch as senior vice president of sales and marketing and named Howard Miller vice president of U.S. sales.
Nuvelo Inc., of Sunnyale, Calif., appointed Mark Perry to its board.
Pluristem Life Sciences Inc., of Haifa, Israel, expanded its board to include Doron Shorrer as chairman, and also Hava Klemperer Meretzki and Robert Pico.
PPD Inc., of Wilmington, N.C., added David Grange to its board.
Prestwick Pharmaceuticals Inc., of Washington, appointed David Cory chief commercial officer.
Senesco Technologies Inc., of New Brunswick, N.J., appointed John Braca to its board.
The Immune Response Corp., of Carlsbad, Calif., appointed Michael Green vice president, finance and chief financial officer.
U.S. Genomics, of Woburn, Mass., added John Canepa as vice president of finance and chief financial officer.
ViroLogic Inc., of South San Francisco, promoted Ken Hitchner to vice president, pharmaceutical collaborations.
Vulcan Inc., of Seattle, added Michael Kranda to its investment management team to oversee its biotechnology portfolio.